A pharmacoeconomic simulation model has been developed to simulate the effect of the three different vaccination programs in the Italian elderly population, during a single influenza season.
Infection rate for the non-vaccinated elderly population was estimated using a random effect model implemented with Italian literature data [4, 5, 6, 7] , and resulted of 16.8%. Rates for influenza related complications were taken from published literature data [8, 9] .
Effectiveness data for the traditional vaccine were derived from a Cochrane metanalysis [10] . Data regarding the reduction in number of ILI cases caused by the adjuvanted vaccine were based on surrogate serological end-points [11] . Data for the reduction in ACS and CVA rates were obtained from a Spanish case-control study [9] .
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The perspective of Italian National Health Service was adopted; direct sanitary costs were considered, according to current Italian prices and tariffs (Tab. II).
To test the robustness of the model, a one-way sensitivity analysis was performed on main parameters.
Vaccination with the MF59 ® adjuvanted vaccine is more effective and cost saving when compared with the standard vaccination or no vaccination, thus representing the optimal strategy for the elderly population.
The standard vaccine, despite a light cost increase, proved to be cost effective compared to the null option.
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Absence of vaccination could lead to more than 2 million ILI cases, 300,000 hospitalizations and 30,000 deaths.
The vaccination programme would lead to an estimated 1.5 million ILI cases with a standard vaccine, and to 1.3 million cases with the MF59 ® adjuvanted vaccine.
Number of hospitalizations is reduced to 270,000 with the traditional vaccine and to 230,000 with the MF59 ® vaccine, and number of deaths is reduced respectively to 18,000 and 16,000.
Total costs related to treatments for ILI and related hospitalizations, without vaccination, result in about 1,060 million Euro for the whole season.
The standard vaccination strategy could produce a moderate direct cost increase of about 45 million Euro (+4.3%), whereas the vaccination with the MF59 ® adjuvanted vaccine could provide an estimated saving of about 80 million Euro (-7.9%).
Cost savings are mainly related to hospital admissions avoided.
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Influenza is one of the major causes of morbidity, hospitalizations and mortality, particularly in the elderly population.
Influenza vaccination has proven effective in the reduction of influenza-like illness (ILI) cases, and therefore in reduction in influenza-related hospitalizations, drug consumption, primary care consultations and deaths.
The innovative MF59 ® adjuvanted vaccine increases immune response especially in the elderly population at high risk for influenza-related complications, and demonstrated an overall good safety profile.
The aim of this study is to assess the relative economic impact in Italy of three different prophylactic strategies:
• vaccination with a standard vaccine • vaccination with the MF59 ® vaccine • no intervention Table III . Number of ILI, hospitalization and death events. One season simulation on the Italian elderly population when no vaccination strategy is adopted (noVacc), or when a vaccination strategy based on a traditional vaccine (Stnd) or on the MF59® adjuvanted vaccine (MF59®) is applied.
